Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Ceragon Networks Reaffirms FY22 Guidance

Outlook We are reaffirming our 2022 revenue guidance of $300 – $315 million, and our 2023 revenue guidance of $325 – $345 million. Our guidance is of course subject to potential downsides and upsides as we continue to
byBenzinga Newsdesk
August 1, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Outlook

We are reaffirming our 2022 revenue guidance of $300 – $315 million, and our 2023 revenue guidance of $325 – $345 million. Our guidance is of course subject to potential downsides and upsides as we continue to address supply chain challenges facing the industry. Our 5-year revenue target is approximately $500 million, and we also target increasing our gross margins to at least 34-36% over the same period.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Clearside Biomedical Announces Pricing Of $15M Registered Direct Offering With Institutional Investors And An Existing Stockholder, Providing For The Purchase And Sale Of 11,111,111 Shares Of Common Stock And Accompanying Warrant

By Benzinga Newsdesk
February 7, 9:23 AM
Clearside Biomedical, Inc. ("Clearside" or the "Company") (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®),

CLSD